These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 19634921

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
    Katsiki N, Hatzitolios AI.
    Curr Opin Obstet Gynecol; 2010 Dec; 22(6):466-76. PubMed ID: 20724929
    [Abstract] [Full Text] [Related]

  • 4. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE.
    Treat Endocrinol; 2006 Dec; 5(3):171-87. PubMed ID: 16677059
    [Abstract] [Full Text] [Related]

  • 5. Insulin-sensitizing agents in polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Eur J Endocrinol; 2006 Jun; 154(6):763-75. PubMed ID: 16728533
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of insulin-sensitizing agents in patients with polycystic ovary syndrome.
    Bloomgarden ZT, Futterweit W, Poretsky L.
    Endocr Pract; 2001 Jun; 7(4):279-86. PubMed ID: 11497481
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
    Nardo LG, Rai R.
    Gynecol Endocrinol; 2001 Oct; 15(5):373-80. PubMed ID: 11727360
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
    Diamanti-Kandarakis E, Zapanti E.
    Ann N Y Acad Sci; 2000 Oct; 900():203-12. PubMed ID: 10818407
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K, Keleştimur F, Bayram F, Sahin Y, Tutuş A.
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?
    Cheang KI, Nestler JE.
    Reprod Biomed Online; 2004 Apr; 8(4):440-7. PubMed ID: 15149568
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.